How to Help Your Patients Find Finacea In Stock: A Provider's Guide

Patient access failures are a growing challenge in dermatology. Many rosacea patients leave their appointment with a prescription for Finacea (azelaic acid 15%) and then spend days trying to get it filled — dealing with insurance rejections, pharmacies that don't stock the foam, or confusion between brand and generic. This guide gives you concrete, actionable strategies to reduce these barriers for your patients.

Why Patients Struggle to Fill Finacea Prescriptions

The barriers are mostly downstream from your prescription pad, but understanding them helps you write prescriptions that anticipate them:

Prior authorization: Many commercial and Medicare Part D plans require PA for azelaic acid, especially brand-name Finacea.

Step therapy: Many plans require documented failure with metronidazole before approving azelaic acid.

Brand confusion: Prescriptions written for "Finacea" by brand can be priced at $400–$600+ retail, leading patients to abandon the prescription.

Foam availability: The foam formulation is less widely stocked than the gel; the foam generic is FDA-approved but not yet widely distributed.

Small pharmacy stocking: Independent and small pharmacies may not routinely stock dermatology specialty products.

Optimizing the Prescription Itself

Small changes to how you write the prescription can significantly reduce the likelihood that a patient will hit a wall at the pharmacy:

Write the generic name: "Azelaic acid 15% gel, 50g, dispense as written" or "Azelaic acid 15% gel, 50g, generic acceptable." This immediately opens the prescription up to multiple lower-cost manufacturers and widely stocked generics.

Default to gel over foam: Unless there is a specific tolerability reason to use foam, prescribe the gel. The foam has a slightly more favorable side effect profile (less burning/stinging), but access is significantly harder.

Submit PA early: Have your MA or front desk initiate the PA at the same time the prescription is sent to the pharmacy. This can prevent the 48–72 hour gap between prescription and fill.

Include relevant clinical details: A brief clinical note ("Patient with moderate papulopustular rosacea; ICD-10 L71.9; failed or not appropriate for metronidazole due to [reason]") strengthens PA approvals.

Guiding Patients to the Right Pharmacy

The pharmacy your patient typically uses may not stock azelaic acid gel. Proactively advising patients on where to look saves them time and reduces drop-off:

Large chain pharmacies (CVS, Walgreens, Walmart, Kroger) are most likely to stock generic azelaic acid 15% gel.

Mail-order pharmacies through the patient's insurance plan often have better stock and may offer 90-day supplies at reduced copay.

Encourage patients to search GoodRx or SingleCare for the lowest cash price near them — generic gel can be as low as $27 with a coupon.

Introducing medfinder to Your Practice

One of the most effective ways to reduce patient access frustration is to recommend medfinder. medfinder calls pharmacies near the patient to check which ones can fill the prescription. The patient simply enters the medication name, dosage, and zip code — and receives results by text. This eliminates the 45-minute process of calling pharmacies one by one.

Consider including a reference to medfinder in your discharge paperwork or prescription handout for patients on Finacea, Soolantra, or other specialty rosacea medications.

What to Tell Patients About Cost

Cost is a major driver of prescription abandonment for dermatology medications. Equip your patients with this information at the point of prescribing:

Generic azelaic acid 15% gel: $27–$50 with a GoodRx or SingleCare coupon (50g tube). This is substantially less than the brand.

Brand Finacea foam: $400–$600+ retail; LEO Pharma offers a savings card (877-678-7494) that may reduce cost for eligible commercially insured patients.

PruGen Solutions program: For generic azelaic acid, eligible commercially insured patients may pay no more than $25 per prescription when enrolled.

Documentation Checklist

For patients where PA is likely, include in the chart:

Rosacea diagnosis with ICD-10 code (L71.0, L71.8, or L71.9)

Severity assessment (mild, moderate, severe)

Prior treatments tried and failed (especially metronidazole)

Clinical rationale for azelaic acid (tolerability, efficacy, skin type considerations)

Date PA submitted and expected turnaround time (communicate to patient)

For more on the current availability landscape for Finacea, see: Finacea Shortage: What Providers Need to Know in 2026